AFcell Medical Changes Its Name to Liventa Bioscience

WEST CONSHOHOCKEN, Pa., Feb. 6, 2014 /PRNewswire/ -- AFcell Medical has announced that it will now operate under the name Liventa Bioscience, effective immediately. The new name is a derivation of the words "live" and "placenta" and better reflects the company's mission to improve the lives of patients through its placental-based advanced biologic tissue forms. 

"We are very excited to announce our new name and corporate identity," said Liventa's Chief Executive Officer, Robin Young. "While our new name does not signify a change in strategy or in the strong business model that we've built, it does better represent the scope and direction that our advanced regeneration technology offerings are heading and our emerging position as the leading innovator in advanced biologics solutions."

Liventa's lead technology platform is AmnioClear^™, a natural tissue covering designed for difficult-to-heal wounds or as a biologically active barrier in critical surgical anatomy. AmnioClear is a combination of amnion and chorion—two layers of the placenta—that work with the body's regenerative processes to help balance healing, regulate inflammation, minimize microbial colonization and restore natural tissue functionality.

Recently, the company introduced a new strategic alliance with Cryoport, Inc. to distribute its products to "point-of-use" US-based orthopedic care providers.  

About Liventa Bioscience
Liventa Bioscience is a privately held, commercial stage biotechnology company focused on bringing advanced biologics to market. Its innovative allograft tissue forms come from living donors and are available through independent distribution. Liventa is currently offering or is in the process of developing a number of advanced orthopedic biologics. These products include human collagen membrane sheets derived from placental tissues, flowable wound coverings, synovial fluid transplants and innovative new soft tissue repair implants.

Liventa's advanced biologics for wound care include a range of placental derived coverings, which promise to significantly improve the cost/efficacy dynamic for chronic wound care patients.  Liventa's strategic partner for wound care solutions is the leading supplier of wound care products in the United States, Chicago based, Medline Inc. In addition to its strategic alliance with Medline, Liventa is also a key strategic partner with Cryoport, Inc. and Crosslink Orthopaedics.

For more information on Liventa, visit www.liventabioscience.com.  

About Robin Young
Liventa Chief Executive Officer, Robin Young has more than three decades of experience in medical technology and is one of the leading regenerative medicine technology experts in the United States.  He is the founder and CEO of the annual New York Stem Cell Summit now in its eighth year. Young is also publisher of Orthopedics This Week, a leading industry journal. He has published more than 1,000 research reports and six books regarding regenerative medicine technologies and markets. Youngwas named "Best on the Street" by the Wall Street Journal and was identified as one of the top ten analysts in the United States by Institutional Investor Magazine.

SOURCE Liventa Bioscience